Dabrafenib plus trametinib results in significantly more responses and longer progression-free survival than standard chemotherapy for pediatric patients with low-grade glioma with BRAF V600 mutations, according to a study ...
Sep 21, 2023
0
16
(HealthDay)—For patients with stage III melanoma with BRAF V600E or V600K mutations, 12 months of adjuvant dabrafenib plus trametinib results in increased survival without relapse or distant metastasis at five years, according ...
Sep 4, 2020
0
3
Dabrafenib (Tafinlar), a BRAF inhibitor approved to treat certain types of adult melanoma, showed activity in pediatric patients with low-grade glioma, according to results published in Clinical Cancer Research, a journal ...
Dec 6, 2019
0
3
Cancer often picks up genetic changes that allow it to resist treatment. But this takes time. How do cancer cells undergoing drug treatment survive long enough to evolve? To answer this question, a study presented at the ...
Apr 16, 2018
0
10
Two immunotherapy drugs currently approved by the U.S. Food and Drug Administration (FDA) for the treatment of melanoma also show promise for treating a rare but aggressive form of papillary thyroid cancer.
Jun 5, 2017
0
0
Latest results from a trial of a combination of two targeted therapies (dabrafenib and trametinib) to treat advanced melanoma have shown that patients are living significantly longer on the combined therapy than patients ...
Sep 28, 2015
0
10
Dabrafenib (trade name: Tafinlar) has been approved since August 2013 for the treatment of advanced melanoma. In January 2014, in an early benefit assessment pursuant to the "Act on the Reform of the Market for Medicinal ...
Apr 9, 2014
0
0
